{"denoms":[{"counts":[{"groupId":"BG000","value":"1098"},{"groupId":"BG001","value":"1101"},{"groupId":"BG002","value":"2199"}],"units":"Participants"}],"groups":[{"description":"Participants were administered paclitaxel, 80 mg/m\\^2, IV infusion QW for maximum of 36 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2 IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated every Q2W for a maximum of 20 weeks supported with G-CSF or GM-CSF treatment.","id":"BG000","title":"Chemotherapy"},{"description":"Participants were administered atezolizumab 840 mg, IV infusion, Q2W in combination with chemotherapy (paclitaxel 80 mg/m\\^2, IV infusion QW for maximum of 22 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2, IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated Q2W for maximum of 17 weeks supported with G-CSF or GM-CSF treatment followed by atezolizumab, 1200 mg IV infusion every Q3W as a maintenance therapy to complete 1 year of atezolizumab treatment from the first dose.","id":"BG001","title":"Atezolizumab and Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.4","value":"52.8"},{"groupId":"BG001","spread":"11.9","value":"52.3"},{"groupId":"BG002","spread":"11.6","value":"52.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1094"},{"groupId":"BG001","value":"1101"},{"groupId":"BG002","value":"2195"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"175"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"906"},{"groupId":"BG001","value":"950"},{"groupId":"BG002","value":"1856"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"168"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"57"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"401"},{"groupId":"BG001","value":"423"},{"groupId":"BG002","value":"824"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"10"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"567"},{"groupId":"BG001","value":"554"},{"groupId":"BG002","value":"1121"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"185"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-Treat (ITT) population included all randomized participants, whether or not the assigned study treatment was received."}